Clinical data on FOLH1‐ targeting with α‐emitters (i.e., two protons and two neutrons) in prostate cancer (PCa) is promising and suggests that α‐emitters could be considered for hypoxic tumours.32 Here, FOLH1 is linked to posterior cortical atrophy.